| Year |
Citation |
Score |
| 2024 |
Mathur R, Wang Q, Schupp PG, Nikolic A, Hilz S, Hong C, Grishanina NR, Kwok D, Stevers NO, Jin Q, Youngblood MW, Stasiak LA, Hou Y, Wang J, Yamaguchi TN, ... ... Berger MS, et al. Glioblastoma evolution and heterogeneity from a 3D whole-tumor perspective. Cell. 187: 446-463.e16. PMID 38242087 DOI: 10.1016/j.cell.2023.12.013 |
0.494 |
|
| 2024 |
Liu SJ, Casey-Clyde T, Cho NW, Swinderman J, Pekmezci M, Dougherty MC, Foster K, Chen WC, Villanueva-Meyer JE, Swaney DL, Vasudevan HN, Choudhury A, Pak J, Breshears JD, Lang UE, ... ... Berger MS, et al. Epigenetic reprogramming shapes the cellular landscape of schwannoma. Nature Communications. 15: 476. PMID 38216587 DOI: 10.1038/s41467-023-40408-5 |
0.686 |
|
| 2023 |
Appin CL, Hong C, Suwala AK, Hilz S, Mathur R, Solomon DA, Smirnov IV, Stevers NO, Shai A, Wang A, Berger MS, Chang SM, Phillips JJ, Costello JF. Whole tumor analysis reveals early origin of the TERT promoter mutation and intercellular heterogeneity in TERT expression. Neuro-Oncology. PMID 38141254 DOI: 10.1093/neuonc/noad231 |
0.495 |
|
| 2023 |
Hadad S, Gupta R, Oberheim Bush NA, Taylor JW, Villanueva-Meyer JE, Young JS, Wu J, Ravindranathan A, Zhang Y, Warrier G, McCoy L, Shai A, Pekmezci M, Perry A, Bollen AW, ... ... Berger MS, et al. "De novo replication repair deficient glioblastoma, IDH-wildtype" is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockade. Acta Neuropathologica. 147: 3. PMID 38079020 DOI: 10.1007/s00401-023-02654-1 |
0.648 |
|
| 2023 |
Chen WC, Choudhury A, Youngblood MW, Polley MC, Lucas CG, Mirchia K, Maas SLN, Suwala AK, Won M, Bayley JC, Harmanci AS, Harmanci A, Klisch TJ, Nguyen MP, Vasudevan HN, ... ... Berger MS, et al. Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses. Nature Medicine. PMID 37944590 DOI: 10.1038/s41591-023-02586-z |
0.681 |
|
| 2023 |
Karschnia P, Dietrich J, Bruno F, Dono A, Juenger ST, Teske N, Young JS, Sciortino T, Häni L, van den Bent M, Weller M, Vogelbaum MA, Morshed RA, Haddad AF, Molinaro AM, ... ... Berger MS, et al. Surgical management and outcome of newly diagnosed glioblastoma without contrast enhancement ('low grade appearance') - a report of the RANO resect group. Neuro-Oncology. PMID 37665776 DOI: 10.1093/neuonc/noad160 |
0.304 |
|
| 2023 |
Schupp PG, Shelton SJ, Brody DJ, Eliscu R, Johnson BE, Mazor T, Kelley KW, Potts MB, McDermott MW, Huang EJ, Lim DA, Pieper RO, Berger MS, Costello JF, Phillips JJ, et al. Deconstructing Intratumoral Heterogeneity through Multiomic and Multiscale Analysis of Serial Sections. Biorxiv : the Preprint Server For Biology. PMID 37645893 DOI: 10.1101/2023.06.21.545365 |
0.523 |
|
| 2023 |
Williams EA, Ravindranathan A, Gupta R, Stevers NO, Suwala AK, Hong C, Kim S, Yuan JB, Wu J, Barreto J, Lucas CG, Chan E, Pekmezci M, LeBoit PE, Mully T, ... ... Berger MS, et al. Novel SOX10 indel mutations drive schwannomas through impaired transactivation of myelination gene programs. Neuro-Oncology. PMID 37436963 DOI: 10.1093/neuonc/noad121 |
0.465 |
|
| 2023 |
Raleigh D, Chen W, Choudhury A, Youngblood M, Polley MY, Lucas CH, Mirchia K, Maas S, Suwala A, Won M, Bayley J, Harmanci A, Harmanci A, Klisch T, Nguyen M, ... ... Berger M, et al. Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses. Research Square. PMID 36993741 DOI: 10.21203/rs.3.rs-2663611/v1 |
0.684 |
|
| 2022 |
Lucas CG, Sloan EA, Gupta R, Wu J, Pratt D, Vasudevan HN, Ravindranathan A, Barreto J, Williams EA, Shai A, Whipple NS, Bruggers CS, Maher O, Nabors B, Rodriguez M, ... ... Berger MS, et al. Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. Acta Neuropathologica. PMID 35945463 DOI: 10.1007/s00401-022-02478-5 |
0.671 |
|
| 2022 |
Gleason JM, Klass SH, Huang P, Ozawa T, Santos RA, Fogarty MM, Raleigh DR, Berger MS, Francis MB. Intrinsically Disordered Protein Micelles as Vehicles for Convection-Enhanced Drug Delivery to Glioblastoma Multiforme. Acs Applied Bio Materials. PMID 35857070 DOI: 10.1021/acsabm.2c00215 |
0.5 |
|
| 2022 |
Haddad AF, Young JS, Morshed RA, Berger MS. FLAIRectomy: Resecting beyond the Contrast Margin for Glioblastoma. Brain Sciences. 12. PMID 35624931 DOI: 10.3390/brainsci12050544 |
0.321 |
|
| 2022 |
Choudhury A, Magill ST, Eaton CD, Prager BC, Chen WC, Cady MA, Seo K, Lucas CG, Casey-Clyde TJ, Vasudevan HN, Liu SJ, Villanueva-Meyer JE, Lam TC, Pu JK, Li LF, ... ... Berger MS, et al. Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities. Nature Genetics. PMID 35534562 DOI: 10.1038/s41588-022-01061-8 |
0.722 |
|
| 2022 |
Mohamed E, Kumar A, Zhang Y, Wang AS, Chen K, Lim Y, Shai A, Taylor JW, Clarke J, Hilz S, Berger MS, Solomon DA, Costello JF, Molinaro AM, Phillips JJ. PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications. Neuro-Oncology. PMID 35287169 DOI: 10.1093/neuonc/noac064 |
0.402 |
|
| 2021 |
Sloan EA, Gupta R, Koelsche C, Chiang J, Villanueva-Meyer JE, Alexandrescu S, Eschbacher JM, Wang W, Mafra M, Ud Din N, Carr-Boyd E, Watson M, Punsoni M, Oviedo A, Gilani A, ... ... Berger MS, et al. Intracranial mesenchymal tumors with FET-CREB fusion are composed of at least two epigenetic subgroups distinct from meningioma and extracranial sarcomas. Brain Pathology (Zurich, Switzerland). e13037. PMID 34821426 DOI: 10.1111/bpa.13037 |
0.304 |
|
| 2021 |
Haddad AF, Young JS, Amara D, Berger MS, Raleigh DR, Aghi MK, Butowski NA. Mouse models of glioblastoma for the evaluation of novel therapeutic strategies. Neuro-Oncology Advances. 3: vdab100. PMID 34466804 DOI: 10.1093/noajnl/vdab100 |
0.523 |
|
| 2021 |
Bush NAO, Young JS, Zhang Y, Dalle Ore CL, Molinaro AM, Taylor J, Clarke J, Prados M, Braunstein SE, Raleigh DR, Chang SM, Berger MS, Butowski NA. A single institution retrospective analysis on survival based on treatment paradigms for patients with anaplastic oligodendroglioma. Journal of Neuro-Oncology. PMID 34125374 DOI: 10.1007/s11060-021-03781-z |
0.504 |
|
| 2021 |
Yu Y, Villanueva-Meyer J, Grimmer MR, Hilz S, Solomon DA, Choi S, Wahl M, Mazor T, Hong C, Shai A, Phillips JJ, Wainer BH, McDermott M, Haas-Kogan D, Taylor JW, ... ... Berger MS, et al. Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas. Neuro-Oncology. PMID 33823014 DOI: 10.1093/neuonc/noab081 |
0.486 |
|
| 2021 |
Young JS, Gogos AJ, Pereira MP, Morshed RA, Li J, Barkovich MJ, Hervey-Jumper SL, Berger MS. Effects of ventricular entry on patient outcome during glioblastoma resection. Journal of Neurosurgery. 1-9. PMID 33418530 DOI: 10.3171/2020.7.JNS201362 |
0.304 |
|
| 2020 |
Sloan EA, Chiang J, Villanueva-Meyer JE, Alexandrescu S, Eschbacher JM, Wang W, Mafra M, Ud Din N, Carr-Boyd E, Watson M, Punsoni M, Oviedo A, Gilani A, Kleinschmidt-DeMasters BK, Coss DJ, ... ... Berger MS, et al. Intracranial mesenchymal tumor with FET-CREB fusion - a unifying diagnosis for the spectrum of intracranial myxoid mesenchymal tumors and angiomatoid fibrous histiocytoma-like neoplasms. Brain Pathology (Zurich, Switzerland). e12918. PMID 33141488 DOI: 10.1111/bpa.12918 |
0.323 |
|
| 2020 |
Magill ST, Vasudevan HN, Seo K, Villanueva-Meyer JE, Choudhury A, John Liu S, Pekmezci M, Findakly S, Hilz S, Lastella S, Demaree B, Braunstein SE, Bush NAO, Aghi MK, Theodosopoulos PV, ... ... Berger MS, et al. Multiplatform genomic profiling and magnetic resonance imaging identify mechanisms underlying intratumor heterogeneity in meningioma. Nature Communications. 11: 4803. PMID 32968068 DOI: 10.1038/s41467-020-18582-7 |
0.721 |
|
| 2020 |
Rodriguez-Almaraz JE, Chang S, Clarke J, Oberheim-Bush NA, Taylor J, Buerki R, Berger M, Zablotska L, Lobach I, Butowski N. A systematic review and meta-analysis examining the effects of cannabis and its derivatives in adults with malignant CNS tumors. Neuro-Oncology Practice. 7: 376-383. PMID 32765889 DOI: 10.1093/Nop/Npaa013 |
0.308 |
|
| 2020 |
Young JS, Gogos AJ, Morshed RA, Hervey-Jumper SL, Berger MS. Molecular characteristics of diffuse lower grade gliomas: what neurosurgeons need to know. Acta Neurochirurgica. PMID 32472378 DOI: 10.1007/s00701-020-04426-2 |
0.311 |
|
| 2020 |
Young JS, Chan AK, Viner JA, Sankaran S, Chan AY, Imershein S, Meary-Miller A, Theodosopoulos PV, Jacques L, Aghi MK, Chang EF, Hervey-Jumper SL, Ward T, Gibson L, Ward MM, ... ... Berger MS, et al. A Safe Transitions Pathway for post-craniotomy neurological surgery patients: high-value care that bypasses the intensive care unit. Journal of Neurosurgery. 1-6. PMID 32470928 DOI: 10.3171/2020.3.Jns192133 |
0.493 |
|
| 2020 |
Magill ST, Rubio RR, Berger MS. Principles of Supplemental Motor Area and Cingulate Tumor Resection With Asleep Trimodal Motor Mapping: 2-Dimensional Operative Video. Operative Neurosurgery (Hagerstown, Md.). PMID 32167140 DOI: 10.1093/ons/opaa036 |
0.545 |
|
| 2020 |
Mathur R, Zhang Y, Grimmer MR, Hong C, Zhang M, Bollam S, Petrecca K, Clarke J, Berger MS, Phillips JJ, Oberheim-Bush NA, Molinaro AM, Chang SM, Costello JF. MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence. Neuro-Oncology. PMID 32166314 DOI: 10.1093/Neuonc/Noaa059 |
0.487 |
|
| 2020 |
Sloan EA, Hilz S, Gupta R, Cadwell C, Ramani B, Hofmann J, Kline CN, Banerjee A, Reddy A, Oberheim Bush NA, Chang S, Braunstein S, Chang EF, Raffel C, Gupta N, ... ... Berger MS, et al. Gliomas arising in the setting of Li-Fraumeni syndrome stratify into two molecular subgroups with divergent clinicopathologic features. Acta Neuropathologica. PMID 32157385 DOI: 10.1007/S00401-020-02144-8 |
0.355 |
|
| 2020 |
Oberheim Bush NA, Yu Y, Villanueva-Meyer J, Grimmer M, Hilz S, Solomon D, Choi S, Mazor T, Hong C, Shai A, Phillips JJ, McDermott M, Haas-Kogan DA, Taylor J, Butowski NA, ... Berger M, et al. Temozolomide-induced hypermutation is associated with high-grade transformation, distant recurrence, and reduced survival after transformation in initially low-grade IDH-mutant diffuse gliomas. Journal of Clinical Oncology. 38: 2506-2506. DOI: 10.1200/Jco.2020.38.15_Suppl.2506 |
0.534 |
|
| 2019 |
Lucas CG, Villanueva-Meyer JE, Whipple N, Oberheim Bush NA, Cooney T, Chang S, McDermott M, Berger M, Cham E, Sun PP, Putnam A, Zhou H, Bollo R, Cheshier S, Poppe MM, et al. Myxoid glioneuronal tumor, PDGFRA p.K385-mutant: clinical, radiologic, and histopathologic features. Brain Pathology (Zurich, Switzerland). PMID 31609499 DOI: 10.1111/Bpa.12797 |
0.425 |
|
| 2019 |
Sloan EA, Cooney T, Oberheim Bush NA, Buerki R, Taylor J, Clarke JL, Torkildson J, Kline C, Reddy A, Mueller S, Banerjee A, Butowski N, Chang S, Mummaneni PV, Chou D, ... ... Berger M, et al. Recurrent non-canonical histone H3 mutations in spinal cord diffuse gliomas. Acta Neuropathologica. PMID 31515627 DOI: 10.1007/S00401-019-02072-2 |
0.518 |
|
| 2019 |
De Witte E, Piai V, Kurteff G, Cai R, Mariën P, Dronkers N, Chang E, Berger M. A valid alternative for in-person language assessments in brain tumor patients: feasibility and validity measures of the new TeleLanguage test. Neuro-Oncology Practice. 6: 93-102. PMID 31386040 DOI: 10.1093/Nop/Npy020 |
0.315 |
|
| 2019 |
Lee JC, Mazor T, Lao R, Wan E, Diallo AB, Hill NS, Thangaraj N, Wendelsdorf K, Samuel D, Kline CN, Banerjee A, Auguste K, Raffel C, Gupta N, Berger M, et al. Recurrent KBTBD4 small in-frame insertions and absence of DROSHA deletion or DICER1 mutation differentiate pineal parenchymal tumor of intermediate differentiation (PPTID) from pineoblastoma. Acta Neuropathologica. PMID 30877433 DOI: 10.1007/S00401-019-01990-5 |
0.629 |
|
| 2019 |
Chandra A, Oh T, Wadhwa H, Shah S, Gupta N, McDermott M, Berger M, Aghi M. RARE-30. PEDIATRIC GLIOBLASTOMA IN THE POST-TEMOZOLOMIDE ERA: OUTCOMES AND CHARACTERISTICS Neuro-Oncology. 21: vi227-vi228. DOI: 10.1093/Neuonc/Noz175.953 |
0.404 |
|
| 2019 |
Young J, Zhang Y, Molinaro A, Taylor J, Clarke J, Prados M, Chang S, Berger M, Butowski N, Ann Oberheim-Bush N. RTHP-33. A SINGLE INSTITUTION RETROSPECTIVE ANALYSIS ON SURVIVAL BASED ON TREATMENT PARADIGMS FOR PATIENTS WITH ANAPLASTIC OLIGODENDROGLIOMA Neuro-Oncology. 21: vi216-vi217. DOI: 10.1093/Neuonc/Noz175.904 |
0.333 |
|
| 2019 |
Calixto-Hope L, Lee J, Sloan E, Hofmann J, Van Ziffle J, Onodera C, Grenert J, Devine P, Kline C, Banerjee A, Clarke J, Taylor J, Ann Oberheim-Bush N, Buerki R, Butowski N, ... Berger M, et al. PATH-38. ROSETTE-FORMING GLIONEURONAL TUMOR IS DEFINED BY FGFR1 ACTIVATING ALTERATIONS WITH FREQUENT ACCOMPANYING PI3K AND MAPK PATHWAY MUTATIONS Neuro-Oncology. 21: vi151-vi152. DOI: 10.1093/Neuonc/Noz175.634 |
0.342 |
|
| 2019 |
Zhang M, Hilz S, Martin M, Hong C, Yu Y, Bollam S, Grimmer M, Looney T, Lowman G, Ganpule G, Phillips J, Shai A, Chang S, Clarke J, Taylor J, ... Berger M, et al. IMMU-11. SPATIOTEMPORAL IMMUNOGENOMIC ANALYSIS OF THE T-CELL REPERTOIRE IN IDH-MUTANT LOWER GRADE GLIOMAS Neuro-Oncology. 21: vi121-vi121. DOI: 10.1093/Neuonc/Noz175.505 |
0.529 |
|
| 2019 |
Hilz S, Hong C, Jalbert L, Mazor T, Martin M, Kumar A, Shelton S, Wong K, Hayes J, Yu Y, Zhang M, Luks T, Olson M, Lafontaine M, Shai A, ... Berger M, et al. GENE-47. A 3D ATLAS TO EVALUATE THE SPATIAL PATTERNING OF GENETIC ALTERATIONS AND TUMOR CELL STATES IN GLIOMA Neuro-Oncology. 21: vi107-vi108. DOI: 10.1093/Neuonc/Noz175.449 |
0.573 |
|
| 2019 |
John Liu S, Vasudevan H, Pekmezci M, Choudhury A, Lien B, Breshears J, Swaney D, Magill S, Lang U, Chen W, Gopinath C, Castro M, Villanueva-Meyer J, Braunstein S, Sneed P, ... Berger M, et al. GENE-37. VESTIBULAR SCHWANNOMA IS COMPRISED OF NEURAL CREST AND IMMUNE SUBGROUPS Neuro-Oncology. 21: vi105-vi105. DOI: 10.1093/Neuonc/Noz175.439 |
0.722 |
|
| 2019 |
Mathur R, Zhang Y, Grimmer M, Hong C, Berger M, Molinaro A, Ann Oberheim-Bush N, Chang S, Costello J. GENE-35. MGMT PROMOTER METHYLATION IN NEWLY DIAGNOSED LGG AS A POTENTIAL BIOMARKER FOR TMZ-ASSOCIATED HYPERMUTATION AT RECURRENCE Neuro-Oncology. 21: vi105-vi105. DOI: 10.1093/Neuonc/Noz175.437 |
0.561 |
|
| 2019 |
Magill S, Vasudevan H, Seo K, John Liu S, Hilz S, Villanueva-Meyer J, Choudhury A, Demaree B, Lim D, Braunstein S, Ann Oberheim-Bush N, Ullian E, Aghi M, Theodosopoulos P, Sneed P, ... Berger M, et al. TMOD-27. A NEURAL CREST CELL SUBPOPULATION UNDERLIES INTRATUMOR HETEROGENEITY IN MENINGIOMA Neuro-Oncology. 21: vi268-vi268. DOI: 10.1093/Neuonc/Noz175.1126 |
0.736 |
|
| 2019 |
Krishna S, Kakaizada S, Valdivia C, Seo K, Raleigh D, Findlay A, Almeida N, Sudharshan R, Choudhury A, Brang D, Nagarajan S, Berger M, Monje M, Hervey-Jumper S. TMIC-46. GLIOMA-INDUCED SYNAPTOGENESIS IS ENRICHED WITHIN FUNCTIONAL CONNECTIVITY NETWORK HUBS AND INFLUENCES LANGUAGE PROCESSING IN ADULT IDH WT GLIOBLASTOMA Neuro-Oncology. 21: vi257-vi258. DOI: 10.1093/Neuonc/Noz175.1080 |
0.561 |
|
| 2019 |
Taylor J, Molinaro A, Rodriguez Almaraz E, Downey C, Phillips J, Ann Oberheim-Bush N, Butowski N, Chang S, Berger M, Prados M, Haas-Kogan D, Clarke J. ACTR-42. PI3K/mTOR PATHWAY ACTIVATION SELECTED PHASE II STUDY OF EVEROLIMUS (RAD001) WITH AND WITHOUT TEMOZOLOMIDE IN THE TREATMENT OF ADULT PATIENTS WITH SUPRATENTORIAL LOW-GRADE GLIOMA [NCT NCT02023905] Neuro-Oncology. 21: vi22-vi23. DOI: 10.1093/Neuonc/Noz175.084 |
0.361 |
|
| 2019 |
Morshed R, Reihl S, Kakaizada S, Zhang E, Young J, Clarke J, Butowski N, Taylor J, Ann Oberheim-Bush N, Aghi M, Berger M, Chang S, Hervey-Jumper S. ACTR-35. A STUDY OF RACE AND SOCIOECONOMIC STATUS IMPACTING THERAPEUTIC CLINICAL TRIAL ENROLLMENT IN ADULT GLIOMAS PATIENTS Neuro-Oncology. 21: vi21-vi21. DOI: 10.1093/Neuonc/Noz175.078 |
0.332 |
|
| 2018 |
Morshed RA, Young JS, Han SJ, Hervey-Jumper SL, Berger MS. Perioperative outcomes following reoperation for recurrent insular gliomas. Journal of Neurosurgery. 1-7. PMID 30239317 DOI: 10.3171/2018.4.JNS18375 |
0.316 |
|
| 2018 |
López GY, Van Ziffle J, Onodera C, Grenert JP, Yeh I, Bastian BC, Clarke J, Oberheim Bush NA, Taylor J, Chang S, Butowski N, Banerjee A, Mueller S, Kline C, Torkildson J, ... ... Berger M, et al. The genetic landscape of gliomas arising after therapeutic radiation. Acta Neuropathologica. PMID 30196423 DOI: 10.1007/S00401-018-1906-Z |
0.416 |
|
| 2018 |
Phillips JJ, Gong H, Chen K, Joseph NM, van Ziffle J, Bastian BC, Grenert JP, Kline CN, Mueller S, Banerjee A, Nicolaides T, Gupta N, Berger MS, Lee HS, Pekmezci M, et al. The genetic landscape of anaplastic pleomorphic xanthoastrocytoma. Brain Pathology (Zurich, Switzerland). PMID 30051528 DOI: 10.1111/Bpa.12639 |
0.309 |
|
| 2018 |
Pekmezci M, Villanueva-Meyer JE, Goode B, Van Ziffle J, Onodera C, Grenert JP, Bastian BC, Chamyan G, Maher OM, Khatib Z, Kleinschmidt-DeMasters BK, Samuel D, Mueller S, Banerjee A, Clarke JL, ... ... Berger M, et al. The genetic landscape of ganglioglioma. Acta Neuropathologica Communications. 6: 47. PMID 29880043 DOI: 10.1186/S40478-018-0551-Z |
0.332 |
|
| 2018 |
Dayani F, Young JS, Bonte A, Chang EF, Theodosopoulos P, McDermott MW, Berger MS, Aghi MK. Safety and outcomes of resection of butterfly glioblastoma. Neurosurgical Focus. 44: E4. PMID 29852771 DOI: 10.3171/2018.3.FOCUS1857 |
0.313 |
|
| 2018 |
Morshed RA, Young JS, Han SJ, Hervey-Jumper SL, Berger MS. The transcortical equatorial approach for gliomas of the mesial temporal lobe: techniques and functional outcomes. Journal of Neurosurgery. 1-9. PMID 29676697 DOI: 10.3171/2017.10.JNS172055 |
0.32 |
|
| 2018 |
Magill ST, Morshed RA, Lucas CG, Aghi MK, Theodosopoulos PV, Berger MS, de Divitiis O, Solari D, Cappabianca P, Cavallo LM, McDermott MW. Tuberculum sellae meningiomas: grading scale to assess surgical outcomes using the transcranial versus transsphenoidal approach. Neurosurgical Focus. 44: E9. PMID 29606045 DOI: 10.3171/2018.1.FOCUS17753 |
0.58 |
|
| 2018 |
Vasudevan HN, Braunstein SE, Phillips JJ, Pekmezci M, Tomlin BA, Wu A, Reis GF, Magill ST, Zhang J, Feng FY, Nicholaides T, Chang SM, Sneed PK, McDermott MW, Berger MS, et al. Comprehensive Molecular Profiling Identifies FOXM1 as a Key Transcription Factor for Meningioma Proliferation. Cell Reports. 22: 3672-3683. PMID 29590631 DOI: 10.1016/J.Celrep.2018.03.013 |
0.688 |
|
| 2018 |
Yu Y, Hilz S, Grimmer M, Solomon D, Choi S, Wahl M, Mazor T, Hong C, Shai A, J Phillips J, Villanueva-Meyer J, McDermott M, Haas-Kogan D, Taylor J, Butowski N, ... ... Berger M, et al. PATH-29. CLINICAL SIGNIFICANCE OF TEMOZOLOMIDE-INDUCED SOMATIC HYPERMUTATION IN INITIALLY LOW-GRADE IDH-MUTANT DIFFUSE GLIOMAS Neuro-Oncology. 20: vi164-vi165. DOI: 10.1093/Neuonc/Noy148.685 |
0.481 |
|
| 2017 |
Magill ST, Han SJ, Li J, Berger MS. Resection of primary motor cortex tumors: feasibility and surgical outcomes. Journal of Neurosurgery. 1-12. PMID 29219753 DOI: 10.3171/2017.5.JNS163045 |
0.566 |
|
| 2017 |
Magill ST, Wang DD, Rutledge WC, Lau D, Berger MS, Sankaran S, Lau CY, Imershein SG. Changing Operating Room Culture: Implementation of a Post-Operative Debrief and Improved Safety Culture. World Neurosurgery. PMID 28843757 DOI: 10.1016/j.wneu.2017.08.090 |
0.482 |
|
| 2017 |
Wahl M, Chang SM, Phillips JJ, Molinaro AM, Costello JF, Mazor T, Alexandrescu S, Lupo JM, Nelson SJ, Berger M, Prados M, Taylor JW, Butowski N, Clarke JL, Haas-Kogan D. Probing the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low-grade gliomas. Cancer. PMID 28759109 DOI: 10.1002/Cncr.30909 |
0.477 |
|
| 2016 |
Wahl M, Phillips J, Molinaro A, Lin Y, Perry A, Haas-Kogan DA, Costello J, Dayal M, Butowski N, Clarke J, Prados M, Berger MS, Nelson S, Chang SM. Omission of Radiation Therapy for Low-Grade Gliomas: Molecular and Radiographic Correlates of Treatment Response and Disease Progression on a Phase 2 Clinical Trial of Adjuvant Temozolomide. International Journal of Radiation Oncology, Biology, Physics. 96: S90. PMID 27676047 DOI: 10.1016/J.Ijrobp.2016.06.227 |
0.417 |
|
| 2016 |
Han SJ, Reis G, Kohanbash G, Shrivastav S, Magill ST, Molinaro AM, McDermott MW, Theodosopoulos PV, Aghi MK, Berger MS, Butowski NA, Barani I, Phillips JJ, Perry A, Okada H. Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma. Journal of Neuro-Oncology. PMID 27624915 DOI: 10.1007/S11060-016-2256-0 |
0.527 |
|
| 2016 |
Wahl M, Phillips JJ, Molinaro AM, Lin Y, Perry A, Haas-Kogan DA, Costello JF, Dayal M, Butowski N, Clarke JL, Prados M, Nelson S, Berger MS, Chang SM. Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide. Neuro-Oncology. PMID 27571885 DOI: 10.1093/Neuonc/Now176 |
0.476 |
|
| 2016 |
Raleigh DR, Seymour ZA, Tomlin B, Theodosopoulos PV, Berger MS, Aghi MK, Geneser SE, Krishnamurthy D, Fogh SE, Sneed PK, McDermott MW. Resection and brain brachytherapy with permanent iodine-125 sources for brain metastasis. Journal of Neurosurgery. 1-7. PMID 27367240 DOI: 10.3171/2016.4.Jns152530 |
0.524 |
|
| 2016 |
Raleigh DR, Solomon DA, Lloyd SA, Lazar A, Garcia MA, Sneed PK, Clarke JL, McDermott MW, Berger MS, Tihan T, Haas-Kogan DA. Histopathologic review of pineal parenchymal tumors identifies novel morphologic subtypes and prognostic factors for outcome. Neuro-Oncology. PMID 27282397 DOI: 10.1093/Neuonc/Now105 |
0.554 |
|
| 2015 |
Englot DJ, Magill ST, Han SJ, Chang EF, Berger MS, McDermott MW. Seizures in supratentorial meningioma: a systematic review and meta-analysis. Journal of Neurosurgery. 1-10. PMID 26636386 DOI: 10.3171/2015.4.JNS142742 |
0.524 |
|
| 2015 |
Hervey-Jumper S, Berger M. Technical nuances of awake brain tumor surgery and the role of maximum safe resection. Journal of Neurosurgical Sciences. PMID 26394241 |
0.304 |
|
| 2015 |
Barajas RF, Pampaloni MH, Clarke JL, Seo Y, Savic D, Hawkins RA, Behr SC, Chang SM, Berger M, Dillon WP, Cha S. Assessing Biological Response to Bevacizumab Using 18F-Fluoromisonidazole PET/MR Imaging in a Patient with Recurrent Anaplastic Astrocytoma. Case Reports in Radiology. 2015: 731361. PMID 25793136 DOI: 10.1155/2015/731361 |
0.34 |
|
| 2015 |
van Thuijl HF, Mazor T, Johnson BE, Fouse SD, Aihara K, Hong C, Malmström A, Hallbeck M, Heimans JJ, Kloezeman JJ, Stenmark-Askmalm M, Lamfers ML, Saito N, Aburatani H, Mukasa A, ... Berger MS, et al. Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment. Acta Neuropathologica. 129: 597-607. PMID 25724300 DOI: 10.1007/S00401-015-1403-6 |
0.497 |
|
| 2015 |
Claus EB, Walsh KM, Wiencke JK, Molinaro AM, Wiemels JL, Schildkraut JM, Bondy ML, Berger M, Jenkins R, Wrensch M. Survival and low-grade glioma: the emergence of genetic information. Neurosurgical Focus. 38: E6. PMID 25552286 DOI: 10.3171/2014.10.Focus12367 |
0.399 |
|
| 2015 |
Shelton S, Johnson B, Mazor T, Potts M, McDermott M, Huang E, Lim D, Pieper R, Berger M, Phillips J, Costello J, Oldham M. MPTH-29CONNECTING MUTANT GENOTYPES TO ABERRANT TRANSCRIPTIONAL SIGNATURES ACROSS SERIAL SECTIONS OF A HUMAN TUMOR Neuro-Oncology. 17: v144.4-v145. DOI: 10.1093/Neuonc/Nov222.29 |
0.573 |
|
| 2015 |
Han S, Reis G, Kohanbash G, Srivastav S, Magill S, Molinaro A, McDermott M, Theodosopoulos P, Aghi M, Berger M, Barani I, Phillips J, Perry A, Okada H. IMPS-11EXPRESSION AND PROGNOSTIC IMPACT OF IMMUNE MODULATORY MOLECULE PD-L1 IN MENINGIOMA Neuro-Oncology. 17: v115.2-v115. DOI: 10.1093/Neuonc/Nov217.11 |
0.567 |
|
| 2015 |
Ojha J, Wrensch M, Pekmezci M, Hansen H, Rice T, McCoy L, Madsen N, Tihan T, Berger M, Chang S, Prados M, Wiemels J, Walsh K, Wiencke J. GENO-29MUTATIONAL DIVERSITY UNDERLYING TELOMERE MAINTENANCE MECHANISMS IN AN APPRECIABLE FRACTION OF ADULT GLIOMAS Neuro-Oncology. 17: v98.1-v98. DOI: 10.1093/Neuonc/Nov215.29 |
0.314 |
|
| 2015 |
Lin A, Berger M. Epig-10Aberrant Epigenome In Glioblastoma Multiforme Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov214.10 |
0.318 |
|
| 2015 |
Walsh K, Pekmezci M, Decker P, Hansen H, Sicotte H, Rice T, Kollmeyer T, McCoy L, Sarkar G, Perry A, Giannini C, Tihan T, Berger M, Molinaro A, Wiemels J, et al. EPID-31ATRX AND TERT ASSAYS PROVIDE NON-REDUNDANT INFORMATION IN ADULT GLIOMA PATIENTS: INCORPORATING TELOMERE MARKERS INTO NEUROPATHOLOGY PRACTICE Neuro-Oncology. 17: v85.1-v85. DOI: 10.1093/Neuonc/Nov213.31 |
0.429 |
|
| 2015 |
Wahl M, Aicardi J, Molinaro A, Haas-Kogan D, Butowski N, Clarke J, Prados M, Phillips J, Berger M, Chang S. ATCT-32A PHASE II STUDY OF TEMOZOLOMIDE IN THE TREATMENT OF ADULT PATIENTS WITH SUPRATENTORIAL LOW-GRADE GLIOMA Neuro-Oncology. 17: v8.4-v9. DOI: 10.1093/Neuonc/Nov206.32 |
0.366 |
|
| 2015 |
Lau D, Hervey-Jumper S, Chang S, Molinaro A, McDermott M, Phillips J, Berger M. ATCT-21A PROSPECTIVE PHASE II CLINICAL TRIAL OF 5-AMINOLEVULINIC ACID TO CORRELATE INTRAOPERATIVE FLUORESCENCE INTENSITY WITH HISTOLOGIC CELLULARITY Neuro-Oncology. 17: v6.1-v6. DOI: 10.1093/Neuonc/Nov206.21 |
0.393 |
|
| 2015 |
Iikhanizadeh S, Miroshnikova Y, Frantz A, Zhu W, Idilli A, Quigley D, Lakins J, Magnitsky S, Phillips J, James D, Berger M, Arosio D, Sun D, Weaver V, Weiss W, et al. ATPS-63OSMOTIC SWELLING REGULATES TUMOR GROWTH AND DRUG UPTAKE IN HUMAN GLIOBLASTOMA Neuro-Oncology. 17: v32.1-v32. DOI: 10.1093/Neuonc/Nov204.63 |
0.38 |
|
| 2015 |
Raleigh D, Lloyd S, Solomon D, Lazar A, Tihan T, Sneed P, Clarke J, Varenika V, Garcia M, Muller S, Berger M, Haas-Kogan D. Outcomes and Prognostic Factors for Pineal Parenchymal Tumors: A 25 Year Single-Institution Experience International Journal of Radiation Oncology*Biology*Physics. 93: E63. DOI: 10.1016/J.Ijrobp.2015.07.704 |
0.572 |
|
| 2015 |
Garcia M, Raleigh D, Maghsoudi K, Braunstein S, Clarke J, Sneed P, Fogh S, Larson D, Nakamura J, Barani I, Mueller S, Berger M, Haas-Kogan D. Outcomes and Salvage Therapy for Recurrent Choroid Plexus Tumors: A 25-Year Single-Institution Experience International Journal of Radiation Oncology*Biology*Physics. 93: E504. DOI: 10.1016/J.Ijrobp.2015.07.1835 |
0.55 |
|
| 2014 |
Hervey-Jumper SL, Berger MS. Role of surgical resection in low- and high-grade gliomas. Current Treatment Options in Neurology. 16: 284. PMID 24595756 DOI: 10.1007/s11940-014-0284-7 |
0.305 |
|
| 2014 |
Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, Fouse SD, Yamamoto S, Ueda H, Tatsuno K, Asthana S, Jalbert LE, Nelson SJ, Bollen AW, Gustafson WC, ... ... Berger MS, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science (New York, N.Y.). 343: 189-93. PMID 24336570 DOI: 10.1126/Science.1239947 |
0.535 |
|
| 2014 |
Huse JT, Wallace M, Aldape KD, Berger MS, Bettegowda C, Brat DJ, Cahill DP, Cloughesy T, Haas-Kogan DA, Marra M, Miller CR, Nelson SJ, Salama SR, Soffietti R, Wen PY, et al. Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma research workshop. Neuro-Oncology. 16: 173-8. PMID 24305708 DOI: 10.1093/Neuonc/Not229 |
0.473 |
|
| 2014 |
Ilkhanizadeh S, Miroshnikova Y, Frantz A, James D, Berger M, McKnight T, Weaver V, Weiss W, Persson A. NT-11 * TARGETING INTERSTITIAL FLUID PRESSURE TO REDUCE TUMOR GROWTH AND INCREASE DRUG UPTAKE IN BRAIN TUMORS Neuro-Oncology. 16: v161-v161. DOI: 10.1093/Neuonc/Nou265.11 |
0.395 |
|
| 2014 |
Hervey-Jumper S, Li J, Lau D, Molinaro A, Perry D, Meng L, Berger M. NC-06 * AWAKE CRANIOTOMY TO MAXIMIZE GLIOMA RESECTION: METHODS AND TECHNICAL NUANCES Neuro-Oncology. 16: v135-v135. DOI: 10.1093/Neuonc/Nou263.6 |
0.391 |
|
| 2014 |
Nagarajan R, Barajas R, Mazor T, Phillips J, Ma J, Hong C, Johnson B, Dayal M, Cha S, Nakamura J, Berger M, Chang S, Furnari F, Taylor B, Costello J. GE-42 * INTEGRATED RADIOGRAPHIC AND PHYLOGENETIC CASE STUDY OF A PRIMARY AND CONTRALATERAL RECURRENT GLIOMA Neuro-Oncology. 16: v105-v106. DOI: 10.1093/Neuonc/Nou256.41 |
0.565 |
|
| 2014 |
Johnson B, Mazor T, Hong C, Barnes M, Yamamoto S, Ueda H, Tatsuno K, Aihara K, Asthana S, Dayal M, Nelson S, Phillips J, Bollen A, Mukasa A, Saito N, ... Berger M, et al. GE-15 * CLONAL EVOLUTION AND INTRATUMORAL HETEROGENEITY OF LOW-GRADE GLIOMA GENOMES Neuro-Oncology. 16: v99-v99. DOI: 10.1093/Neuonc/Nou256.15 |
0.588 |
|
| 2014 |
Han S, Martin A, Berger M, Prados M, Chang S, Clarke J, Bankiewicz K, Butowski N. AT-25 * A PHASE I STUDY OF CONVECTION-ENHANCED DELIVERY OF LIPOSOMAL-IRINOTECAN USING REAL-TIME IMAGING WITH GADOLINIUM IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA Neuro-Oncology. 16: v14-v14. DOI: 10.1093/Neuonc/Nou237.25 |
0.309 |
|
| 2014 |
Clarke JL, Chang S, Phillips J, Molinaro A, Berger M, Nelson S, Haas-Kogan D. EVEROLIMUS (RAD001) AND THE MTOR PATHWAY IN LOW-GRADE GLIOMAS Neuro-Oncology. 16: iii48-iii48. DOI: 10.1093/Neuonc/Nou209.24 |
0.446 |
|
| 2013 |
Safaee M, Clark AJ, Bloch O, Oh MC, Singh A, Auguste KI, Gupta N, McDermott MW, Aghi MK, Berger MS, Parsa AT. Surgical outcomes in choroid plexus papillomas: an institutional experience. Journal of Neuro-Oncology. 113: 117-25. PMID 23468001 DOI: 10.1007/s11060-013-1097-3 |
0.33 |
|
| 2013 |
Hiniker A, Lee HS, Chang S, Berger M, Perry A. Cortical ependymoma with unusual histologic features. Clinical Neuropathology. 32: 318-23. PMID 23458270 DOI: 10.5414/Np300593 |
0.318 |
|
| 2013 |
Adachi K, Sasaki H, Nagahisa S, Yoshida K, Hattori N, Nishiyama Y, Kawase T, Hasegawa M, Abe M, Hirose Y, Alentorn A, Marie Y, Poggioli S, Alshehhi H, Boisselier B, ... ... Berger M, ... ... Berger MS, ... ... Berger M, et al. OMICS AND PROGNSTIC MARKERS Neuro-Oncology. 15: iii136-iii155. DOI: 10.1093/Neuonc/Not183 |
0.425 |
|
| 2012 |
Rutkowski MJ, Jian BJ, Bloch O, Chen C, Sughrue ME, Tihan T, Barani IJ, Berger MS, McDermott MW, Parsa AT. Intracranial hemangiopericytoma: clinical experience and treatment considerations in a modern series of 40 adult patients. Cancer. 118: 1628-36. PMID 21837675 DOI: 10.1002/Cncr.26411 |
0.311 |
|
| 2012 |
Butowski NA, Berger M. Malignant Gliomas: Part I Contemporary Neurosurgery. 34: 1-5. DOI: 10.1097/01.Cne.0000413591.22318.C0 |
0.323 |
|
| 2011 |
Kane AJ, Sughrue ME, Rutkowski MJ, Shangari G, Fang S, McDermott MW, Berger MS, Parsa AT. Anatomic location is a risk factor for atypical and malignant meningiomas Cancer. 117: 1272-1278. PMID 21381014 DOI: 10.1002/cncr.25591 |
0.307 |
|
| 2010 |
Hashizume R, Gupta N, Berger MS, Banerjee A, Prados MD, Ayers-Ringler J, James CD, VandenBerg SR. Morphologic and molecular characterization of ATRT xenografts adapted for orthotopic therapeutic testing. Neuro-Oncology. 12: 366-76. PMID 20308314 DOI: 10.1093/Neuonc/Nop033 |
0.305 |
|
| 2010 |
Sughrue ME, Sanai N, Shangari G, Parsa AT, Berger MS, McDermott MW. Outcome and survival following primary and repeat surgery for World Health Organization Grade III meningiomas: Clinical article Journal of Neurosurgery. 113: 202-209. PMID 20225922 DOI: 10.3171/2010.1.JNS091114 |
0.312 |
|
| 2009 |
Hodgson JG, Yeh RF, Ray A, Wang NJ, Smirnov I, Yu M, Hariono S, Silber J, Feiler HS, Gray JW, Spellman PT, Vandenberg SR, Berger MS, James CD. Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts. Neuro-Oncology. 11: 477-87. PMID 19139420 DOI: 10.1215/15228517-2008-113 |
0.307 |
|
| 2008 |
McLendon R, Friedman A, Bigner D, Van Meir EG, Brat DJ, Mastrogianakis GM, Olson JJ, Mikkelsen T, Lehman N, Aldape K, Yung WKA, Bogler O, Weinstein JN, VandenBerg S, Berger M, et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways Nature. 455: 1061-1068. PMID 18772890 DOI: 10.1038/Nature07385 |
0.324 |
|
| 2007 |
Dinca EB, Sarkaria JN, Schroeder MA, Carlson BL, Voicu R, Gupta N, Berger MS, James CD. Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy. Journal of Neurosurgery. 107: 610-6. PMID 17886562 DOI: 10.3171/JNS-07/09/0610 |
0.301 |
|
| 2006 |
Keles GE, Chang EF, Lamborn KR, Tihan T, Chang CJ, Chang SM, Berger MS. Volumetric extent of resection and residual contrast enhancement on initial surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. Journal of Neurosurgery. 105: 34-40. PMID 16871879 DOI: 10.3171/Jns.2006.105.1.34 |
0.31 |
|
| 2006 |
Rubenstein JL, Fridlyand J, Shen A, Aldape K, Ginzinger D, Batchelor T, Treseler P, Berger M, McDermott M, Prados M, Karch J, Okada C, Hyun W, Parikh S, Haqq C, et al. Gene expression and angiotropism in primary CNS lymphoma. Blood. 107: 3716-23. PMID 16418334 DOI: 10.1182/Blood-2005-03-0897 |
0.366 |
|
| 2005 |
Wrensch M, Fisher JL, Schwartzbaum JA, Bondy M, Berger M, Aldape KD. The molecular epidemiology of gliomas in adults. Neurosurgical Focus. 19: E5. PMID 16398469 DOI: 10.3171/Foc.2005.19.5.6 |
0.422 |
|
| 2005 |
Liang Y, Diehn M, Watson N, Bollen AW, Aldape KD, Nicholas MK, Lamborn KR, Berger MS, Botstein D, Brown PO, Israel MA. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proceedings of the National Academy of Sciences of the United States of America. 102: 5814-9. PMID 15827123 DOI: 10.1073/Pnas.0402870102 |
0.305 |
|
| 2005 |
Parney IF, Kunwar S, McDermott M, Berger M, Prados M, Cha S, Croteau D, Puri RK, Chang SM. Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma. Journal of Neurosurgery. 102: 267-75. PMID 15739554 DOI: 10.3171/Jns.2005.102.2.0267 |
0.365 |
|
| 2004 |
Larson DA, Suplica JM, Chang SM, Lamborn KR, McDermott MW, Sneed PK, Prados MD, Wara WM, Nicholas MK, Berger MS. Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme Neuro-Oncology. 6: 119-126. PMID 15134626 DOI: 10.1215/S1152851703000425 |
0.313 |
|
| 2003 |
Prados MD, McDermott M, Chang SM, Wilson CB, Fick J, Culver KW, Van Gilder J, Keles GE, Spence A, Berger M. Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: A phase I/II multi-institutional trial Journal of Neuro-Oncology. 65: 269-278. PMID 14682377 DOI: 10.1023/B:Neon.0000003588.18644.9C |
0.365 |
|
| 2003 |
Weber F, Asher A, Bucholz R, Berger M, Prados M, Chang S, Bruce J, Hall W, Rainov NG, Westphal M, Warnick RE, Rand RW, Floeth F, Rommel F, Pan H, et al. Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. Journal of Neuro-Oncology. 64: 125-37. PMID 12952293 DOI: 10.1007/Bf02700027 |
0.333 |
|
| 2003 |
Chang SM, Parney IF, McDermott M, Barker FG, Schmidt MH, Huang W, Laws ER, Lillehei KO, Bernstein M, Brem H, Sloan AE, Berger M. Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the Glioma Outcome Project. Journal of Neurosurgery. 98: 1175-81. PMID 12816260 DOI: 10.3171/Jns.2003.98.6.1175 |
0.368 |
|
| 2003 |
Schmidt MH, Berger MS, Lamborn KR, Aldape K, McDermott MW, Prados MD, Chang SM. Repeated operations for infiltrative low-grade gliomas without intervening therapy. Journal of Neurosurgery. 98: 1165-9. PMID 12816258 DOI: 10.3171/Jns.2003.98.6.1165 |
0.309 |
|
| 2002 |
Berger M, Char DH. Interactive image guidance for surgical localization of orbital apical tumors. Orbit (Amsterdam, Netherlands). 21: 199-203. PMID 12187413 DOI: 10.1076/Orbi.21.3.199.7180 |
0.35 |
|
| 2001 |
Hirose Y, Aldape K, Bollen A, James CD, Brat D, Lamborn K, Berger M, Feuerstein BG. Chromosomal abnormalities subdivide ependymal tumors into clinically relevant groups American Journal of Pathology. 158: 1137-1143. PMID 11238062 DOI: 10.1016/S0002-9440(10)64061-8 |
0.344 |
|
| 2001 |
Asher AL, Weber F, Bucholz R, Berger M, Prados M, Bruce J, Hall W, Rainov NG, Westphal M, Warnick R, Williams RL, Hingorani VN, Puri RK. 763 Safety, Tolerability and Tumor Response of IL4-toxin (NBI-3001) in Patients with Recurrent Malignant Glioma Neurosurgery. 49: 525-525. DOI: 10.1097/00006123-200108000-00127 |
0.355 |
|
| 2000 |
Ojemann SG, Sneed PK, Larson DA, Gutin PH, Berger MS, Verhey L, Smith V, Petti P, Wara W, Park E, McDermott MW. Radiosurgery for malignant meningioma: results in 22 patients Journal of Neurosurgery. 93: 62-67. DOI: 10.3171/jns.2000.93.supplement_3.0062 |
0.316 |
|
| 1999 |
Keles GE, Anderson B, Berger MS. The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. Surgical Neurology. 52: 371-9. PMID 10555843 DOI: 10.1016/S0090-3019(99)00103-2 |
0.302 |
|
| 1998 |
Wisoff JH, Boyett JM, Berger MS, Brant C, Li H, Yates AJ, McGuire-Cullen P, Turski PA, Sutton LN, Allen JC, Packer RJ, Finlay JL. Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children's Cancer Group trial no. CCG-945. Journal of Neurosurgery. 89: 52-9. PMID 9647172 DOI: 10.3171/jns.1998.89.1.0052 |
0.31 |
|
| 1996 |
Skirboll SS, Ojemann GA, Berger MS, Lettich E, Winn HR. Functional cortex and subcortical white matter located within gliomas. Neurosurgery. 38: 678-84; discussion 6. PMID 8692384 DOI: 10.1227/00006123-199604000-00008 |
0.378 |
|
| 1994 |
Morrison RS, Yamaguchi F, Saya H, Bruner JM, Yahanda AM, Donehower LA, Berger M. Basic fibroblast growth factor and fibroblast growth factor receptor I are implicated in the growth of human astrocytomas. Journal of Neuro-Oncology. 18: 207-16. PMID 7964981 DOI: 10.1007/Bf01328955 |
0.362 |
|
| 1994 |
Rostomily RC, Spence AM, Duong D, McCormick K, Bland M, Berger MS. Multimodality management of recurrent adult malignant gliomas: results of a phase II multiagent chemotherapy study and analysis of cytoreductive surgery. Neurosurgery. 35: 378-88; discussion 3. PMID 7800129 DOI: 10.1227/00006123-199409000-00004 |
0.34 |
|
| 1992 |
Bourne JP, Geyer R, Berger M, Griffin B, Milstein J. The prognostic significance of postoperative residual contrast enhancement on CT scan in pediatric patients with medulloblastoma. Journal of Neuro-Oncology. 14: 263-70. PMID 1460489 DOI: 10.1007/Bf00172602 |
0.344 |
|
| 1985 |
Pertuiset B, Dougherty D, Cromeyer C, Hoshino T, Berger M, Rosenblum ML. Stem cell studies of human malignant brain tumors. Part 2: Proliferation kinetics of brain-tumor cells in vitro in early-passage cultures. Journal of Neurosurgery. 63: 426-432. PMID 4020471 DOI: 10.3171/Jns.1985.63.3.0426 |
0.381 |
|
| Show low-probability matches. |